Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics posts new September 2026 corporate presentation on fasedienol trial data

Neutral Impact 2 of 5 other Written later

Vistagen Therapeutics filed a Form 8-K furnishing a new corporate presentation, dated September 2026, which the company began using on September 25, 2026. The presentation reviews its fasedienol Phase 3 program, where only PALISADE-2 met its primary endpoint, and it does not report new financial results or guidance.

Key points

  • PALISADE-2 met its primary endpoint with a 5.8-point improvement over placebo (p=0.015), while PALISADE-1, PALISADE-3 and PALISADE-4 did not reach statistical significance on their primary endpoints.
  • The presentation states that the Repeat Dose Study was not powered to demonstrate statistical significance and that its pooled primary endpoint result was not statistically significant (p=0.2).
  • The filing includes Exhibit 99.1 and the XBRL cover page, and is signed by President and CEO Shawn K. Singh.

The filing

CompanyVistagen Therapeutics, Inc. (VTGN)
Form8-K, current report
Filed with the SECSep 25, 2026, 9:11 AM ET
Accession number0001628280-26-063510

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.